Greenspace Health vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
Collaborative care platform for mental health measurement and outcomes tracking, Toronto Canada. Helps health systems use data to improve patient mental health outcomes.
About
Greenspace Health is a Toronto, Canada-based digital health company founded in 2015 that provides a collaborative care platform designed to embed measurement-based care practices into mental health and primary care settings. The platform enables clinicians and care teams to systematically collect, track, and act on patient-reported outcome measures (PROMs), bringing data-driven decision-making to mental health treatment in a way that mirrors how chronic disease management is handled in other medical specialties.\n\nThe Greenspace platform supports the collection of validated clinical measurement tools such as the PHQ-9 (depression), GAD-7 (anxiety), and dozens of other standardized instruments, delivered to patients via mobile or web between sessions. Clinicians receive visualized outcome trends, alerts for deteriorating patients, and population-level dashboards that allow managers to identify care gaps and resource needs. The system is designed to integrate with existing EHRs and fit into existing clinical workflows rather than replace them.\n\nGreenspace primarily serves health systems, community mental health centers, and primary care organizations in Canada and the United States that are implementing collaborative care models or value-based mental health contracts. As payers and government health agencies increase pressure on providers to demonstrate mental health treatment outcomes, Greenspace is positioned as essential infrastructure for outcomes accountability. The company has partnered with several provincial health systems in Canada and is expanding its US footprint through health system partnerships.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.